KORU Medical Systems Inc. (KRMD)
(Delayed Data from NSDQ)
$2.67 USD
+0.03 (1.07%)
Updated Jul 12, 2024 10:10 AM ET
3-Hold of 5 3
D Value B Growth C Momentum C VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
KRMD 2.67 +0.03(1.07%)
Will KRMD be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for KRMD based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for KRMD
KORU Medical's (KRMD) FreedomEdge Gets Regulatory Nod in Japan
KORU Medical Systems Inc. (KRMD) Reports Q1 Loss, Tops Revenue Estimates
KRMD: What are Zacks experts saying now?
Zacks Private Portfolio Services
ClearPoint Neuro, Inc. (CLPT) Reports Q4 Loss, Tops Revenue Estimates
KORU Medical (KRMD) Forms New Deal on Subcutaneous Infusion
Silk Road Medical (SILK) Reports Q4 Loss, Tops Revenue Estimates
Other News for KRMD
KORU Medical Systems Receives Regulatory Clearance for FreedomEdge® Infusion System in Japan
Buy Rating for REPRO-MED Systems Amid Strategic Oncology Infusion Advances and SCHOTT Pharma Collaboration
Simplifying Subcutaneous Drug Administration: SCHOTT Pharma and KORU Medical Systems Announce Collaboration to Advance Large Volume Subcutaneous Infusion
Koru and Schott team to advance large volume subcutaneous infusion
Lake Street Remains a Buy on REPRO-MED Systems (KRMD)